Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | CPS1 | P31327 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26088683 | 1.00 | HCAR2 (0.39) | HCAR2HRH3JAK3PIK3CGAR | |
| SCHEMBL4573559 | 0.81 | HRH3 (0.45) | HRH3JAK3PIK3CGCXCR3FFAR4 | |
| SCHEMBL26089849 | 0.79 | HCAR2 (0.39) | HCAR2JAK3AR | |
| SCHEMBL26089473 | 0.79 | HCAR2 (0.39) | HCAR2JAK3AR | |
| SCHEMBL26090094 | 0.73 | HCAR2 (0.50) | HCAR2CPS1 | |
| SCHEMBL26089066 | 0.73 | HCAR2 (0.50) | HCAR2CPS1 | |
| SCHEMBL26088631 | 0.72 | HCAR2 (0.68) | HCAR2 | |
| SCHEMBL26089556 | 0.72 | HCAR2 (0.68) | HCAR2 | |
| SCHEMBL2730333 | 0.70 | RAB9A (0.50) | HCAR2HRH3HDAC1 | |
| SCHEMBL8113244 | 0.69 | MAP4K4 (0.52) | HRH3PIK3CGCXCR3HDAC1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | HCAR2 76/4885HRH3 104/4885JAK3 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.